kSep Systems, a five-year-old startup focusing on centrifuges, recently was sold to a French firm in a deal valued at $28 million.
Sartorius Stedim Biotech disclosed is buy of kSep last month. It said staff and management in Morrisville will be retained.
“Sartorius Stedim Biotech’s strong relationships with its customers will significantly speed up our internationalization and business growth. SSB will provide access to considerably more customers, especially in Asia, a market we haven’t developed yet,” said Sunil Mehta, CEO of kSep, in the deal announcement.
Based in Aubagne, France, Sartorius is an international supplier for biopharmaceutical companies.
kSep develops and sells single-use, fully automated centrifugation systems used for manufacturing biopharmaceuticals, such as vaccines, cell-based therapeutics and monoclonal antibodies, according to Sartorius.
The company is expected to generate $7 million in revenue this year.
“kSep’s centrifuges are a very innovative, single-use cell separation technology that perfectly complements our offering for downstream bioprocessing,” said Sartorius board member.
“Our clients will greatly benefit from the unique ability to collect, wash and concentrate cells quickly and reduce both the time and cost of downstream purification steps.”
A profile of kSep
kSep Systems leverages its innovation, engineering, and cGMP manufacturing expertise to provide robust and automated single-use centrifugation solutions for the manufacturing of recombinant therapeutics, cell therapy products, and vaccines. kSep products solve the problems of traditional centrifugation-based systems by providing a gentle processing environment for the concentration, washing, and separation of cells while maintaining high recoveries. kSep Systems, a spinoff from KBI Biopharma, Inc., was established in 2011 and is based in Morrisville, NC.